Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LP-98 in Healthy Subjects
NCT05933824Phase 1Completed
- Sponsor
- Shanxi Kangbao Biological Products
- Start
- Jul 2023
- Primary completion
- Apr 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of lipovirtide in human immunodeficiency virus infection (HIV) (11 arms), sponsored by Shanxi Kangbao Biological Products. Primary endpoints: Changes from baseline in respiration rate, Changes from baseline in blood pressure and 38 more. Started Jul 2023; status: completed.
02
Drugs
lipovirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05933824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933824.